A carregar...
TAT-Modified ω-Conotoxin MVIIA for Crossing the Blood-Brain Barrier
As the first in a new class of non-opioid drugs, ω-Conotoxin MVIIA was approved for the management of severe chronic pains in patients who are unresponsive to opioid therapy. Unfortunately, clinical application of MVIIA is severely limited due to its poor ability to penetrate the blood-brain barrier...
Na minha lista:
| Publicado no: | Mar Drugs |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6562543/ https://ncbi.nlm.nih.gov/pubmed/31083641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/md17050286 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|